NYSE
BIO
Last Price
US $298.34
KEY FIGURES
MKT CAP
$8.1B
EPS
TTM
$6.26
PEG
TTM
-
P/E
TTM
47.65x
P/S
TTM
3.11x
YIELD
0.00%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
2.40%
Return on equity
ROIC: 1.95%
Valuation History
48.5X
Price to Earnings
EV/EBITDA: 18.9X
Cash flow
Profit margin
0.29%
(FY vs FY)
EBITDA Y/Y
-24.45%
(FY vs FY)
Cash flow Y/Y
-4.69%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $298.34
-68.01%
Default assumptions
EBITDA Multiple
Fair Value
Market $298.34
-71.04%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Bio-Rad Laboratories, Inc. cash flow to debt ratio of 34.76% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.
Financial stability - Healthy cash flow growth.
Bio-Rad Laboratories, Inc.'s free cash flow has increased 40.72% from $266.20M last year to $374.60M, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
Bio-Rad Laboratories, Inc.'s debt to equity ratio is 0.20, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Bio-Rad Laboratories, Inc.'s debt has decreased relative to shareholder equity from 0.21 last year to 0.20 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Bio-Rad Laboratories, Inc. has a net debt to EBITDA ratio of 0.80x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Bio-Rad Laboratories, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial stability - Profit margin growth.
Bio-Rad Laboratories, Inc.'s profit margin has increased (-109.07%) in the last year from -71.86% to 6.52%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Bio-Rad Laboratories, Inc.'s short-term assets of $2.91G exceed its short-term liabilities of $517.00M
Decreasing performance - ROA.
Bio-Rad Laboratories, Inc.'s return on assets of 1.72% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Bio-Rad Laboratories, Inc.'s return on equity of 2.40%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Bio-Rad Laboratories, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Bio-Rad Laboratories, Inc. had positive net income in only 2.00 out of 5 years, indicating unstable earnings
Increasing performance - Free cash flow.
Bio-Rad Laboratories, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Bio-Rad Laboratories, Inc. has a free cash flow yield of 4.64%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Increasing performance - Healthy earnings growth.
Bio-Rad Laboratories, Inc.'s yearly earnings has increased -141.20% since last year from $-1.84G to $759.90M, signaling increasing performance
Increasing performance - Healthy revenue growth.
Bio-Rad Laboratories, Inc.'s yearly revenue has increased 0.65% since last year from $2.57G to $2.58G, signaling increasing performance
Decreasing performance - ROIC.
ROIC 1.95% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Bio-Rad Laboratories, Inc.'s 3-year revenue CAGR of -2.68% is negative, indicating declining revenue over the past 3 years
Decreasing performance - Revenue consistency.
Bio-Rad Laboratories, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance
Decreasing performance - ROE consistency.
Bio-Rad Laboratories, Inc. had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Bio-Rad Laboratories, Inc. is overvalued relative to its fair value price of 95.45 based on Discounted Cash Flow model
Overvalued - Earnings yield.
Bio-Rad Laboratories, Inc. has an earnings yield of 2.10%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings
Overvalued - EBITDA valuation.
Bio-Rad Laboratories, Inc. is overvalued relative to its fair value price of 86.41 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Bio-Rad Laboratories, Inc. has an EV/EBITDA ratio of 7.25x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
Bio-Rad Laboratories, Inc. has no meaningful EPS growth rate; PEG ratio cannot be computed.
Undervalued - P/B ratio.
Bio-Rad Laboratories, Inc. has a price-to-book ratio of 1.17x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Bio-Rad Laboratories, Inc. has a price-to-sales ratio of 3.11x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue